Iron Mountain Incorporated (IRM) grew with the stock adding 0.62% or $0.23 to close at $37.62 on light trading volume of 1.11M compared its three months average trading volume of 1.51M. The Boston Massachusetts 02110 based company operating under the Business Software & Services industry has been trending up for the last 52 weeks, with the shares price now 45.52% up for the period and up by 15.83% so far this year. With price target of $40.8 and a 52.42% rebound from 52-week low, Iron Mountain Incorporated has plenty of upside potential, making it a hold with a view buy.
Iron Mountain Incorporated, together with its subsidiaries, provides storage and information management services in North America, Europe, Latin America, and the Asia Pacific. It operates through North American Records and Information Management Business, North American Data Management Business, Western European Business, and Other International Business segments. The company provides storage and information management services for physical records and other media, such as microfilm and microfiche, master audio and videotapes, film, X-rays, and blueprints, including healthcare information services, vital records services, and service and courier operations, as well as the collection, handling, disposal of sensitive documents for corporate customers. It also offers information destruction services primarily consist of physical secure shredding operations; document management solutions to develop, implement, and support storage and information management solutions for the complete lifecycle of its customers’ information; fulfillment services; technology escrow services that protect and manage source code; and professional consulting services, as well as sells resultant waste paper to third-party recyclers. In addition, the company is involved in the storage and rotation of backup computer media operations, including records management, data protection and recovery, server and computer backup services, and digital content repository systems to house, distribute, and archive key media assets, as well as for storage, safeguarding, and electronic or physical delivery of physical media primarily for the entertainment and media industry clients. It serves commercial, legal, banking, healthcare, accounting, insurance, entertainment, and government organizations. Iron Mountain Incorporated was founded in 1951 and is headquartered in Boston, Massachusetts.
WMIH Corp. (WMIH) dropped $-0.05 to close the day at a new closing price of $1.35, a -3.57% decrease in value from its previous closing price that moved the stock 3.85% above its 52 week low of $1.3. A total of 1.1M shares exchanged hands during the day compared with its three month average trading volume of 943.48K. The stock, which fluctuated between $1.3 and $1.4 during the day, currently situated -46% below its 52 week high. The stock is down by -6.9% in the past one month and down by -18.18% over the past three months. With a one year target estimate of $0 and RSI of 40.74, the stock still has upside potential, making it a hold for now.
WMIH Corp., through its subsidiary, WM Mortgage Reinsurance Company, Inc., engages in reinsurance business with respect to mortgage insurance in runoff mode. The company was formerly known as WMI Holdings Corp. and changed its name to WMIH Corp. in May 2015. WMIH Corp. was founded in 1889 and is headquartered in Seattle, Washington.
PDL BioPharma, Inc. (PDLI) shares were down in last trading by -0.44% to $2.25. It experienced lighter than average volume on day. The stock increased in value by almost 0.45% over the past week and fell -1.75% in the past month. It is currently trading 2.72% above its 50 day moving average and -23.38% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -40.55% decrease in value from its one year high of $3.84. The RSI indicator value of 54.75, lead us to believe that it is a hold for now.
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. has license agreements with various biotechnology and pharmaceutical companies, as well as acquires royalty and other assets. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.